ReviewCurrent cardiology reports2022
Eradicating Atherosclerosis: Should We Start Statins at Younger Ages and at Lower LDL-Cs.
Review in Current cardiology reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 12 citations in OpenAlex.
- Distribution of LDL-Cholesterol Levels and Their Associations With Cardiovascular Outcomes in Young Adults Under 40 Years in South Korea: A Nationwide Cohort Study.Journal of lipid and atherosclerosis · 2026Article
- External validation of the PREVENT risk score: performance and clinical utility in an Iranian population.Scientific reports · 2026Article
- Article
- Article
- Sex differences in the treatment with PCSK9 monoclonal antibodies- real world experience from a dedicated preventive cardiology clinic.American journal of preventive cardiology · 2025Article
- Protective effect of Salvianolic acid B against atherosclerosis: a preclinical systematic review and meta-analysis.Frontiers in pharmacology · 2025Article
- Hyperlipidemia and Cardiovascular Risk in Children and Adolescents.Biomedicines · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
purpose of reviewGiven the increasing burden of cardiovascular disease, we review the literature for earlier initiation of statin therapy at younger ages and lower low-density lipoprotein cholesterol (LDL-C) levels, with the goal of preventing the development of atherosclerosis prior to clinical events. RECENT
findingsThere is a rising prevalence of dyslipidemia among younger adults. Although guidelines offer recommendations for adults over 40, there is little guidance for the management of younger adults with moderately elevated LDL-C levels. Earlier and more aggressive statin use may slow progression, or even halt atherosclerosis, and may likewise be beneficial and cost-effective on a population level. Further research is needed to define the exact age and LDL-C level at which to start statin therapy. Until then, more detailed risk stratification with lab testing and imaging should be used to identify younger adults at the highest risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.